iSpecimen partners with TriMetis to ‘transform’ tissue-based research

By Isabel Cameron

- Last updated on GMT

© Getty Images
© Getty Images

Related tags biospecimen Partnership Technology AI

iSpecimen, an online marketplace connecting scientists requiring biospecimens for medical research with healthcare specimen providers, has partnered with tissue technology company TriMetis Life Sciences.

The collaboration aims to provide opportunities for iSpecimen, as well as its suppliers and customers, to utilize technology solutions from TriMetis.

“This pilot program exemplifies the fusion of two online portals, leveraging cutting-edge technological tools to both enhance customer service and elevate industry standards. For both iSpecimen and TriMetis, the focus is first and foremost on establishing best practices for quality control and assurance,” said Tracy Curley, CEO of iSpecimen.

“By incorporating AI readings and images, our goal is to enhance the standardization of tissue-based oncology samples on the iSpecimen Marketplace, contributing to a transformative shift in the quality assessments of tissue samples. Our collaboration with TriMetis represents a milestone in advancing tissue research quality, streamlining procurement processes and setting new industry-wide benchmarks through this innovative process that will further increase accuracy.”

By combining iSpecimen’s network of suppliers and researchers with TriMetis’ AI solutions, the partnership is also working to address industry challenges – such as reducing the risk of errors associated with manual processes.

ISpecimen and TriMetis will initially focus on a substantial subset of solid tumor types, standardizing tissue sample evaluation through TriMetis’ AI technology.

In addition, the initiative is hoping to make ‘significant strides’ in the comprehensive analysis of cancer tissues.

This will be accomplished by providing researchers and suppliers access to TriMetis’ ARCH Ecosystem for end-to-end management of digital images, biospecimens, associated data and AI information via the integration of TriMetis’ solutions into iSpecimen’s platform.  

Phil Cestaro, CEO of TriMetis Life Sciences, commented: “At TriMetis, we are committed to advancing cancer research through software solutions and cutting-edge AI technologies for laboratories, researchers, and biospecimen providers. Our ARCH software solutions and TCAP AI reduce the time and cost of research by providing critical data and eliminating returns to ensure researchers get the samples they need. We strongly believe that through partnerships like this, we can deliver better outcomes for patients all over the world.

“TriMetis’ TCAP AI and image management capabilities, combined with iSpecimen’s platform, is a significant step towards revolutionizing tissue-based research. Our AI-driven approach not only benefits iSpecimen’s suppliers by increasing efficiency but also enhances the overall opportunity for client success. This innovative partnership illustrates how two potentially competitive platforms can work together for the benefit of their clients and customers.”

Related topics Markets & Regulations

Related news

Follow us